Comparative Pharmacology
Head-to-head clinical analysis: TRIPLE SULFA versus TRIPLE SULFOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPLE SULFA versus TRIPLE SULFOID.
TRIPLE SULFA vs TRIPLE SULFOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), blocking folate synthesis essential for nucleic acid production.
Triple sulfoid (sulfadiazine, sulfamethazine, sulfamerazine) competes with para-aminobenzoic acid (PABA) to inhibit dihydropteroate synthase, blocking bacterial folate synthesis.
1 g orally every 12 hours for 10 days (as sulfadiazine, sulfamethazine, and sulfamerazine combination).
2 tablets orally every 6 hours for 10-14 days; each tablet contains sulfadiazine 270 mg, sulfamerazine 270 mg, and sulfamethazine 270 mg.
None Documented
None Documented
6-12 hours (sulfadiazine 10-13h, sulfamerazine 16-24h, sulfamethazine 7-12h); prolonged in renal impairment.
10-12 hours in normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min)
80-90% renal (glomerular filtration and tubular secretion) as unchanged drug and acetylated metabolites; 5-10% biliary/fecal.
Renal: ~70% as unchanged drug; hepatic metabolism: ~20%; fecal: ~10%
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic